CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment

Malignant hematologic diseases, also referred to as hematologic tumors, encompass a series of malignant proliferative disorders of the lymphopoietic system, including leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. The dysregulation of inflammatory factors or chronic inflamma...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanquan Liu, Huanwen Tang
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/15/5/716
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849711021354123264
author Yanquan Liu
Huanwen Tang
author_facet Yanquan Liu
Huanwen Tang
author_sort Yanquan Liu
collection DOAJ
description Malignant hematologic diseases, also referred to as hematologic tumors, encompass a series of malignant proliferative disorders of the lymphopoietic system, including leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. The dysregulation of inflammatory factors or chronic inflammatory responses plays an indispensable role in the onset and progression of these tumors. The C-X-C motif chemokine receptor (CXCR) serves as a key mediator of immune-inflammatory responses. Through its specific regulatory mechanisms, CXCR is involved in the transduction and activation of various signaling pathways, thereby mediating the malignant biological characteristics of blood tumor cells, such as uncontrolled proliferation, differentiation, invasion, migration, autophagy, and apoptosis. In the bone marrow microenvironment, CXCR plays a pivotal role. This review systematically analyzes and elucidates the roles and mechanisms of the CXCR family in hematologic malignancies, aiming to provide new insights into the biological mechanisms and clinical significance of these diseases. The CXCR family holds great potential as a molecular marker for both fundamental research and the clinical diagnosis and treatment of hematologic malignancies.
format Article
id doaj-art-e6dadf1bc3394f2fae7dfdf90f1f1178
institution DOAJ
issn 2218-273X
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Biomolecules
spelling doaj-art-e6dadf1bc3394f2fae7dfdf90f1f11782025-08-20T03:14:45ZengMDPI AGBiomolecules2218-273X2025-05-0115571610.3390/biom15050716CXCR Family and Hematologic Malignancies in the Bone Marrow MicroenvironmentYanquan Liu0Huanwen Tang1Department of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, The First School of Clinical Medicine, Guangdong Medical University, Dongguan 523808, ChinaDepartment of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan 523808, ChinaMalignant hematologic diseases, also referred to as hematologic tumors, encompass a series of malignant proliferative disorders of the lymphopoietic system, including leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. The dysregulation of inflammatory factors or chronic inflammatory responses plays an indispensable role in the onset and progression of these tumors. The C-X-C motif chemokine receptor (CXCR) serves as a key mediator of immune-inflammatory responses. Through its specific regulatory mechanisms, CXCR is involved in the transduction and activation of various signaling pathways, thereby mediating the malignant biological characteristics of blood tumor cells, such as uncontrolled proliferation, differentiation, invasion, migration, autophagy, and apoptosis. In the bone marrow microenvironment, CXCR plays a pivotal role. This review systematically analyzes and elucidates the roles and mechanisms of the CXCR family in hematologic malignancies, aiming to provide new insights into the biological mechanisms and clinical significance of these diseases. The CXCR family holds great potential as a molecular marker for both fundamental research and the clinical diagnosis and treatment of hematologic malignancies.https://www.mdpi.com/2218-273X/15/5/716CXC chemokine receptorhematologic malignancieslymphopoietic systemcarcinogenic mechanismstherapeutic targets
spellingShingle Yanquan Liu
Huanwen Tang
CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
Biomolecules
CXC chemokine receptor
hematologic malignancies
lymphopoietic system
carcinogenic mechanisms
therapeutic targets
title CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
title_full CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
title_fullStr CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
title_full_unstemmed CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
title_short CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment
title_sort cxcr family and hematologic malignancies in the bone marrow microenvironment
topic CXC chemokine receptor
hematologic malignancies
lymphopoietic system
carcinogenic mechanisms
therapeutic targets
url https://www.mdpi.com/2218-273X/15/5/716
work_keys_str_mv AT yanquanliu cxcrfamilyandhematologicmalignanciesinthebonemarrowmicroenvironment
AT huanwentang cxcrfamilyandhematologicmalignanciesinthebonemarrowmicroenvironment